title: Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil, and concomitant radiotherapy for poor-prognosis head and neck cancer.
abstract: Concomitant chemoradiotherapy holds promise in the therapy of advanced head and neck cancer. We have previously reported on the combination of 5-fluorouracil, hydroxyurea, and concomitant chemoradiotherapy administered on an alternate-week basis. In this ongoing study, we are testing the feasibility of adding continuous-infusion paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this combination. Background information and early clinical data are presented.
authors.affiliation: Department of Medicine, University of Chicago, IL, USA.
authors.forename: E E
authors.initials: EE
authors.lastname: Vokes
authors.forename: R
authors.initials: R
authors.lastname: Stupp
authors.forename: D
authors.initials: D
authors.lastname: Haraf
authors.forename: W
authors.initials: W
authors.lastname: Moran
authors.forename: D
authors.initials: D
authors.lastname: Malone
authors.forename: B
authors.initials: B
authors.lastname: Wenig
authors.forename: P
authors.initials: P
authors.lastname: Sweeney
authors.forename: R R
authors.initials: RR
authors.lastname: Weichselbaum
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D007262:Infusions, Intravenous; D017239:Paclitaxel / Q000008:administration & dosage
chemical_list: D017239:Paclitaxel; D005472:Fluorouracil; D006918:Hydroxyurea